KOMZIFTI (Ziftomenib) Patent Expiration, LOE Window & CMS Spending

KOMZIFTI (Ziftomenib) by Kura Oncology: FDA Orange Book core substance LOE 2044-07-16, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $48,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKura Oncology
FDA Application & PathwayN220305 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2044-07-16
Last Listed Patent or Exclusivity Date2044-07-16
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($48,500 intro WAC)